Recce Pharmaceuticals Ltd. announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327). Recce is exploring multiple infusion times of 15, 20, 30, and 45 minutes, and 1 hour at 3,000mg, which is viewed as R327?s optimal dosing therapeutic window. The Company has established that the dose of 3,000mg, administered at varying infusion times between 15 and 60 minutes, has been proven safe in participants.

The efficacy of R327 via intravenous administration will be made available at the completion of the Phase I/II trial in line with the study protocol.